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In recent years there has been an explosion in the use of multi-gene panels to test for cancer 
predisposition often utilising large panels across many tumour types. More recently the results of 
these tests have been used as a form of case control study to assess genes for cancer associations, 
especially with breast cancer. Case control analysis is arguably the most informative method to 
identify gene-cancer associations as it also provides confirmation of the level of any increased risk. 
Ideally the ‘cases’ should be derived from a truly unselected series of individuals with the relevant 
cancer. Similarly the controls should come from the same population, and can be either true 
‘population’ controls from representative, unselected and ideally age matched individuals, or ‘super’ 
controls (older/age matched individuals known not to have the malignancy being investigated). 
Particularly for rare diseases (present in less than 1 in 2000 individuals), very large case control 
series are required to confirm moderate risk elevations of only 2-3 fold. Whilst traditional methods 
such as positional cloning from family linkage were used for identifying the BRCA1 and BRCA2 genes 
in 1994 and 1995, most other breast cancer predisposition genes were identified as causal from 
candidate gene approaches using case control series often enhanced by using familial samples. 
However, even these have identified potentially spurious associations, because analyses of 
breast/ovarian cancer families has identified a real association with ‘ovarian’ cancer, but a 
potentially false association with breast cancer1,2.  In particular, initial breast cancer associations 
with RAD51C, RAD51D and BRIP1 were later called into question with breast cancer specific analysis 
1,2. Hence, these three genes are not on the UK’s National Health Service breast cancer panel,3 but 
they do appear on most commercial ‘breast cancer’ specific panels. Other DNA repair gene 
associations, such as for ATM, CHEK2 and PALB2, have been well validated in multiple cohort studies 
and added to breast cancer specific gene panels.3  In contrast to the aforementioned genes which 
have no recognisable syndromic phenotype for an individual, the phenotypes from germline 
pathogenic variants in NF1, PTEN and STK11 (table 1) are usually easily recognisable in single 
individuals and there are well validated diagnostic criteria which allow a clinical diagnosis without 
the need for molecular confirmation.4,5  
Four recent articles based on multi-gene panel testing, published in high impact oncology journals, 
have nonetheless concluded that there are no associations between pathogenic variants in these 
three syndromic genes (NF1, PTEN and STK11) and breast cancer risk.6-9 Whilst these analyses have 
identified potential new gene associations, the negative results concerning syndromic associations 
should be tempered. In the first of their three articles Ambry’s 21 panel gene test6 was evaluated in 
41,611 consecutively tested white women with breast cancer. In the second7 9,639 patients with 
breast cancer were assessed, whilst the third assessed the risk of triple negative breast cancer in 
8,753 women. Whilst two studies used control data from the ExAc database6,8 the second used a 
combination of controls tested for non-cancer indications.7 The larger initial study6 identified NF1 
gene variants in 0.1% compared to 0.11% in ExAc controls. No control frequency was provided for 
the second study although a frequency of around 0.15% was said to be non-significant8. The third 
study also found a frequency of 0.15% in triple negative breast cancer which was also non-
significant. 8 The first two studies effectively excluded BRCA1 and BRCA2 as they confirmed that 
there had been a high degree of pre-testing for these genes. The first also excluded what they 
‘termed’ ‘syndromic’ genes including PTEN, CDH1 and TP53. However, it is unclear why 
neurofibromatosis 1, caused by pathogenic variants in the NF1 gene, was not also excluded as being 
syndromic, as it is far more recognisable from patient characteristics than even PTEN hamartoma 
syndrome.4 
There are two main flaws in the conclusions that NF1 is not associated with breast cancer. The first is 
that panel testing for breast cancer is selective based on family history, age and patient/clinician 
choice. A clinician who already has an ‘explanation’ for a breast cancer in a patient with NF1 is 
unlikely to send off for a gene panel. Indeed the syndromic learning problems associated with NF1 
may also preclude gainful employment and thus reimbursement for panel testing. The link to breast 
cancer based on cohort studies is now irrefutable with six studies reporting Odds Ratios of 4-11 fold 
for NF1 women aged <50 years of age10,11. Furthermore, driver NF1 pathogenic variants have been 
identified in the Cancer Genome Atlas and from NF1 patients are associated with higher tumour 
grade and Human Epidermal Growth Factor Receptor 2 (HER2) overexpression,10,12,13 further 
evidence against a chance association. The link with breast cancer and NF1 has been established 
since at least 200711. All of the reported panel tests were performed since March 20126-8, after four 
of the cohort studies had reported showing a probable causal association with breast cancer and 
NF111. The authors of the Ambry reports clearly admit that there was already preselection for BRCA 
testing6-8. If a clinician wished to test for NF1 they would use a substantially more sensitive RNA 
based approach than a panel14. A similar concern should also be expressed for the apparent lack of 
association with PTEN in the second and third Ambry studies7,8 as these were not powered to assess 
the lower frequency of PTEN pathogenic variants and suffer from the same issue of lack of 
requirement for a panel test when an explanation for breast cancer was already present. The same 
criticism can be put forward for the absence of STK11 variants being identified in 2000 familial breast 
cancer samples tested in the LIFEPOOL study.9 Peutz-Jeghers disease caused by STK11 variants is 
easily identified by peri-oral pigmentation and usually presents symptomatically in early life with 
multiple intestinal polyps (Table 1). 
The second potential flaw is the use of ExAc controls. The very high frequency of apparent 
pathogenic variants of 1/900 is simply not consistent with the estimates of birth incidence from 
highly ascertained populations of between 1 in 2,000-2,60015,16. Due to early deaths in NF1 patients 
prevalence in an adult population is nearer 1 in 3,000-4,500.15,16 It is therefore unclear whether this 
high estimate in controls is due to over assessment of pathogenic variants, selection for children to 
have exomes with NF1 features or due to some variants being silent clinically.  
Whilst panel tests appear to be a useful agnostic test for cancer associations with non-syndromic 
genes, they are not when considering easily recognisable syndromes, as these create biases in 
selection against any association and may also contaminate controls. The only way to robustly assess 
for links with syndromes in a case control study is for ALL patients with breast cancer to be tested on 
a population basis with appropriate controls tested of a similar age, also without selection.  
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Table 1: Syndromic genes identifiable from clinical features in a single woman that increase 
breast cancer risk from cohort studies 
 
Gene Syndrome Birth 
incidence 
Clinical features Breast 
cancer risk 
to 50 
yrs/lifetime   
Other 
malignancy 
risk 
NF1 Neurofibromatosis 1 1 in 2,000-
2,500 
Café au lait 
Cutaneous 
neurofibromas 
Iris Lisch nodules 
10%/20% Malignant 
peripheral 
nerve sheath 
tumor, glioma 
PTEN PTEN hamartoma 
syndrome (Cowden)3 
1 in 
100,000-
200,000 
Macrocephaly, 
mucocutaneous 
lesions (eg 
Trichilemmomas) 
50%/85% Thyroid, 
endometrial 
STK11 Peutz-Jeghers4 1:25,000 to 
1:280,000 
Peri-oral 
pigmentation, 
hamartomatous 
bowel polyps 
Nk/37-55% Colorectal, 
stomach, 
small bowel, 
ovary, cervix, 
pancreas, 
testes 
 
 
